Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae
Open accessThe DOI matches its Crossref record; 56 of the 59 references it cites were found in a registry or an index.
Abstract
Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) may serve as a new assay for drug testing in a human context, but their validity particularly for the evaluation of inotropic drug effects remains unclear. In this blinded analysis, we compared the effects of 10 indicator compounds with known inotropic effects in electrically stimulated (1.5 Hz) hiPSC-CM-derived 3-dimensional engineered heart tissue (EHT) and human atrial trabeculae (hAT). Human EHTs were prepared from iCell hiPSC-CM, hAT obtained at routine heart surgery. Mean intra-batch variation coefficient in baseline force measurement was 17% for EHT and 49% for hAT. The PDE-inhibitor milrinone did not affect EHT contraction force, but increased force in hAT. Citalopram (selective serotonin reuptake inhibitor), nifedipine (LTCC-blocker) and lidocaine (Na+ channel-blocker) had negative inotropic effects on EHT and hAT. Formoterol (beta-2 agonist) had positive lusitropic but no inotropic effect in EHT, and positive clinotropic, lusitropic, and inotropic effects in hAT. Tacrolimus (calcineurin-inhibitor) had a negative inotropic effect in EHTs, but no effect in hAT. Digoxin (Na+-K+-ATPase-inhibitor) showed a positive inotropic effect only in EHTs, but no effect in hAT probably due to short incubation time. Ryanodine (ryanodine receptor-inhibitor) reduced contraction force in both models. Rolipram and acetylsalicylic acid showed noninterpretable results in hAT. Contraction amplitude and kinetics were more stable over time and less variable in hiPSC-EHTs than hAT. HiPSC-EHT faithfully detected cAMP-dependent and -independent positive and negative inotropic effects, but limited beta-2 adrenergic or PDE3 effects, compatible with an immature CM phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Blinded drug screening of 10 compounds. Average contraction peaks. A, Average contraction peaks of electrically stimulated hiPSC-EHTs in modified Tyrode‘s solution (1.0 mM Ca2+) indicating relative force normalized to baseline over time. Four to eight EHTs per average peak. Black: baseline. Red: compound at indicated concentration (30 µM milrinone, 30 µM rolipram, 10 µM citalopram, 0.1 µM nifedipine, 30 µM lidocaine, 0.3 µM formoterol, 30 µM tacrolimus, 0.3 µM digoxin, 30 µM acetylsalicylic acid, 30 µM, and 0.3 µM [blue] ryanodine). B, Average contraction peaks of electrically stimulated hAT in modified Tyrode‘s solution (1.8 mM Ca2+). Four to six hAT per average peak. Black: baseline. Green: compound at indicated concentration (30 µM milrinone, 30 µM rolipram, 10 µM citalopram, 3 µM nifedipine, 30 µM lidocaine, 3 µM formoterol, 30 µM tacrolimus, 3 µM digoxin, 30 µM acetylsalicylic acid, 30 µM, and 3 µM [blue] ryanodine). Please note the different ordinate scale in the milrinone graph of the hAT measurement and the different concentrations of nifedipine, formoterol and digoxin in hiPSC-EHT versus hAT.](https://figures.cochat.ai/paper-figures/7181a45016ca45adb931ab13af475cdb/blinded-contractility-analysis-in-hipsc-cardiomyocytes-in-engineered-heart-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Prior cardiac tissue engineering studies have shown this in the context of arrhythmogenicity [33], contractility [14,34] and recapitulation of disease phenotypes [12,48].”
From Bioengineering an electro-mechanically functional miniature ventricular heart chamber from human pluripotent stem cells (2018) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium Sparks: Elementary Events Underlying Excitation-Contraction Coupling in Heart Muscle
Cheng, H., Lederer, W. J., & Cannell, M. B. (1993) · Science · doi:10.1126/science.8235594 · Cited by 1,935
Development of a drug screening platform based on engineered heart tissue
Hansen, A., Eder, A., Bönstrup, M., Flato, M., Mewe, M., Schaaf, S., Aksehirlioglu, B., Schwörer, A., Uebeler, J., & Eschenhagen, T. (2010) · Circulation Research · doi:10.1161/circresaha.109.211458 · Cited by 510
Self-citationHuman Engineered Heart Tissue: Analysis of Contractile Force
Mannhardt, I., Breckwoldt, K., Letuffe-Brenière, D., Schaaf, S., Schulz, H., Neuber, C., Benzin, A., Werner, T., Eder, A., Schulze, T., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.04.011 · Cited by 398
Self-citationPrediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes
Braam, S. R., Tertoolen, L., van de Stolpe, A., Meyer, T., Passier, R., & Mummery, C. L. (2010) · Stem Cell Research · doi:10.1016/j.scr.2009.11.004 · Cited by 368
Hirt, M. N., Boeddinghaus, J., Mitchell, A., Schaaf, S., Börnchen, C., Müller, C., Schulz, H., Hubner, N., Stenzig, J., Stoehr, A., et al. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.05.009 · Cited by 352
Self-citationNavarrete, E. G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C., Gong, T., Sharma, A., Burridge, P. W., Patlolla, B., Lee, A. S., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000570 · Cited by 302
Denning, C., Borgdorff, V., Crutchley, J., Firth, K. S. A., George, V., Kalra, S., Kondrashov, A., Hoang, M. D., Mosqueira, D., Patel, A., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.014 · Cited by 293 · cited 2×
“In hiPSC-CM models isoprenaline was frequently used and was reported to lead to small effects across different models (effect size: <þ100%; Denning et al., 2016) compared to human nonfailing heart tissue (effect sizes more than 200%; Bohm et al., 1991; Mügge et al., 1985; Schotten et al., 2001),…”
MethodCrumb, W. J., Vicente, J., Johannesen, L., & Strauss, D. G. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.03.009 · Cited by 288
Guo, L., Abrams, R. M. C., Babiarz, J. E., Cohen, J. D., Kameoka, S., Sanders, M. J., Chiao, E., & Kolaja, K. L. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr158 · Cited by 272
Blinova, K., Stohlman, J., Vicente, J., Chan, D., Johannesen, L., Hortigon-Vinagre, M. P., Zamora, V., Smith, G., Crumb, W. J., Pang, L., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfw200 · Cited by 272
Cited by
Challenges and opportunities for the next generation of cardiovascular tissue engineering
Cho, S., Discher, D. E., Leong, K. W., Vunjak-Novakovic, G., & Wu, J. C. (2022) · Nature Methods · doi:10.1038/s41592-022-01591-3 · Cited by 176
Li, R. A., Keung, W., Cashman, T. J., Backeris, P. C., Johnson, B. V., Bardot, E. S., Wong, A. O. T., Chan, P. K. W., Chan, C. W. Y., & Costa, K. D. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.024 · Cited by 175
In vitro generation of functional murine heart organoids via FGF4 and extracellular matrix
Lee, J., Sutani, A., Kaneko, R., Takeuchi, J., Sasano, T., Kohda, T., Ihara, K., Takahashi, K., Yamazoe, M., Morio, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18031-5 · Cited by 154
Natural Biomaterials for Cardiac Tissue Engineering: A Highly Biocompatible Solution
Majid, Q. A., Fricker, A. T. R., Gregory, D. A., Davidenko, N., Hernandez Cruz, O., Jabbour, R. J., Owen, T. J., Basnett, P., Lukasiewicz, B., Stevens, M., et al. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.554597 · Cited by 131
Engineered Cardiac Tissues Generated in the Biowire II: A Platform for Human-Based Drug Discovery
Feric, N. T., Pallotta, I., Singh, R. K., Bogdanowicz, D. R., Gustilo, M. M., Chaudhary, K. W., Willette, R. N., Chendrimada, T. P., Xu, X., Graziano, M. P., et al. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz168 · Cited by 102
Metadata
- Authors
- Mannhardt, I., Eder, A., Dumotier, B., Prondzynski, M., Krämer, E., Traebert, M., Söhren, K.-D., Flenner, F., Stathopoulou, K., Lemoine, M. D., Carrier, L., Christ, T., Eschenhagen, T., & Hansen, A.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- Novartis (Switzerland) (CH)
- Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
- Universität Hamburg (DE)
- Corresponding author
- Hansen, Arne
- ORCID
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-04-27
- Volume
- 158
- Issue
- 1
- Pages
- 164-175
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- PMC
- PMC5837217
- OpenAlex
- W2610084826
- Cited by
- 68
- References
- 59
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 13 · 2023: 8 · 2022: 7 · 2021: 6 · 2020: 13 · 2019: 12 · 2018: 3
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Toxicological Sciences (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- German Centre for Cardiovascular Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- hiPSC-derived cardiomyocytes, engineered heart tissue, lusitropic effect, cardiomyocyte contractility, drug testing, cAMP signaling, beta2-adrenergic agonists, phosphodiesterase III inhibitor, digoxin, tacrolimus, nifedipine, citalopram, lidocaine, formoterol, ryanodine, cardiomyocyte maturation
- MeSH terms
- Calcium, Heart Atria, Humans, Myocardial Infarction, Quality Control, Tissue Engineering, Myocytes, Cardiac, Induced Pluripotent Stem Cells, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae. https://app.cochat.ai/papers/10.1093/toxsci/kfx081
- The paper
- Mannhardt, I., Eder, A., Dumotier, B., Prondzynski, M., Krämer, E., Traebert, M., Söhren, K.-D., Flenner, F., Stathopoulou, K., Lemoine, M. D., Carrier, L., Christ, T., Eschenhagen, T., & Hansen, A. (2017). Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfx081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.